CAR-T for Autoimmune Disease: From Cancer to Refractory SLE/SSc/MS/ITP
B-cell-depleting cell therapies (CAR-T, CAR-Treg, BiTEs, anti-CD19/anti-BCMA) migrating from oncology into refractory autoimmune disease. Tracks: efficacy/safety in SLE, SSc, idiopathic inflammatory myopathy, MS, ITP, T1D; in-vivo CAR delivery (KLN-1010); manufacturing capacity vs. oncology demand; long-term immunodeficiency risk; competitive biologics (belimumab, anifrolumab, obinutuzumab, telitacicept, TYK2 inhibitors).
Timeline
Acta Neurologica scoping review: CAR-T applications in neurology — across 33 studies (Jan 2020 - Dec 2025), CAR-T showed promising efficacy in CNS lymphoma (44% response in glioblastoma trials) and…
Comprehensive review (IJITSS 2026) of 2024-2026 CAR-T / CAR-Treg trials in severe SLE and SSc — confirms favorable efficacy and safety across published cohorts.
BJH review: CAR-T for refractory immune thrombocytopenia — early evidence of sustained remission off treatment in disease where conventional therapies typically fail.
Sci Transl Med: anti-IGHV4-34 CAR-T cells specifically eliminate neoplastic and autoimmune B cells — preserves non-self-reactive B cells while depleting the IGHV4-34 subset enriched in aggressive…
Frontiers in Immunology review: CAR-T and BiTE in rheumatic autoimmune diseases — 15 SSc patients all achieving disease remission with anti-CD19 CAR-T, no grade ≥3 CRS or long-term B-cell aplasia. 12…